SCHEMBL3300866

SCHEMBL3300866

COc1ccc(CNc2nc3c(c(=O)n2-c2ccccc2)CN(C(=O)Nc2cccc(F)c2)CC3)cc1

nearest known ligand 0.45

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PRLHR P49683 5/20 0.44
PDE10A Q9Y233 2/20 0.44
USP2 O75604 3/20 0.43
ALDH1A1 P00352 2/20 0.43
TSHR P16473 2/20 0.43
RECQL P46063 1/20 0.42
HSD17B10 Q99714 1/20 0.42
CYP1A2 P05177 2/20 0.42
CYP3A4 P08684 2/20 0.42
CYP2C19 P33261 2/20 0.42
MAPT P10636 1/20 0.42
CYP2C9 P11712 1/20 0.42
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
HPGD P15428 1/20 0.41
CLPP Q16740 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3297966 0.94 PRLHR (0.45) PRLHRPDE10AALDH1A1RECQLMAPT
SCHEMBL3301167 0.92 PRLHR (0.48) PRLHRPDE10AALDH1A1RECQLMAPT
SCHEMBL3301087 0.92 RECQL (0.47) PRLHRPDE10AALDH1A1RECQLMAPT
SCHEMBL3299970 0.91 PRLHR (0.45) PRLHRPDE10AALDH1A1RECQLMAPT
SCHEMBL3298474 0.91 PRLHR (0.45) PRLHRPDE10AALDH1A1RECQLMAPT
SCHEMBL3299804 0.91 LMNA (0.50) PRLHRTSHRRECQLHSD17B10MAPT
SCHEMBL3297733 0.91 PRLHR (0.44) PRLHRPDE10AUSP2ALDH1A1TSHR
SCHEMBL3297316 0.90 PRLHR (0.46) PRLHRPDE10AALDH1A1RECQLMAPT
SCHEMBL3303376 0.90 PRLHR (0.44) PRLHRPDE10AALDH1A1RECQLMAPT
SCHEMBL3296568 0.90 PRLHR (0.45) PRLHRALDH1A1TSHRRECQLHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8232282-B2 Compound having bicyclic pyrimidine structure and pharmaceutical composition comprising the same DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-07-31 US disclosed
US-20100093771-A1 Compound having bicyclic pyrimidine structure and pharmaceutical composition comprising the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-04-15 US disclosed
EP-2078719-A1 COMPOUND HAVING BICYCLIC PYRIMIDINE STRUCTURE AND PHARMACEUTICAL COMPOSITION COMPRISING THE COMPOUND Dainippon Sumitomo Pharma Co., Ltd. (JP) 2009-07-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100093771-A1 Compound having bicyclic pyrimidine structure and pharmaceutical composition comprising the same GART, MGAT2, MGAT1 PRLHR 3093/4885PDE10A 2176/4885USP2 4271/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.